Venetoclax and Relapsed/Refractory Chronic Lymphocytic Lymphoma
DECEMBER 11, 2016
Jeffrey Jones, MD, MPH
Jeffrey Jones, MD, MPH of Ohio State University talks about the safety and efficacy of venetoclax monotherapy in patients with relapsed or refractory CLL.
Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016